Related Experiment Video
Updated: Jun 30, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning
Frédéric Lapostolle1, Stephen W Borron, Carine Verdier
1SAMU 93, EA 3409, Hôpital Avicenne, Bobigny, France. frederic.lapostolle@avc.ap-hop-paris.fr
Objective:
Despite administration of Fab fragments in digitalis poisoning, high mortality rates are consistently reported. A previous study suggested that Fab fragments prescribed as first-line therapy might improve mortality rate. Our objective was to evaluate this approach.
Design:
Retrospective chart review (January 1990 to January 2004).
Setting:
University hospital intensive care unit.
Patients:
Consecutive patients admitted for cardiac glycoside poisoning.
Intervention:
First-line therapy with Fab fragments (with or without atropine) in either curative or prophylactic doses.
Measurements And Main Results:
A total of 141 patients were admitted for digitalis poisoning of whom 66 received first-line Fab fragment therapy. Their median age was 74 years (25th to 75th percentiles: 51-83); 76% were women. Half were intoxicated by digitoxin and half by digoxin. Median serum concentration was 168 (108-205) ng/mL for digitoxin and 6.2 (4.3-13.5) ng/mL for digoxin. Conduction disturbances were reported in 45 cases (68%) and ventricular arrhythmia in six cases (9%). Fab fragments were administered as curative treatment in 21 patients (32%) and prophylactically in 45 patients (68%). The median cumulative dose was 4 (4-6) vials. No adverse effects were reported. Five patients (7.6%) died.
Conclusions:
First-line therapy with Fab fragments in patients with digitalis poisoning was associated with a low mortality rate.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
